drugset / Trial / NCT02097953
Influence of Rifampin Co-Administration on the Pharmacokinetic Profile of Daptomycin
Phase 0
Completed
12 enrolled
University of Utah
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to understand how an antibiotic, rifampin, may change the blood levels of another antibiotic, daptomycin, in the body. In addition, the effect of polymorphisms in P-glycoprotein (a protein involved in the removal of daptomycin from the body) on the blood levels of daptomycin will be evaluated. The hypotheses are that rifampin will decrease the blood levels of daptomycin and that the effect will be greater for certain P-glycoprotein polymorphisms.
Timeline
- Start
- 2014-05
- Primary completion
- 2015-06
- Completion
- 2016-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Daptomycin | Other / unclassified | 6 mg/kg | Intravenous |
| Subject | Rifampin | Small molecule | 600 mg | Oral |
Indications
No indication recorded.